Clinical Trial Update: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TQ-B3525 tablets combined with osimertinib in advanced non-small cell lung cancer across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib Mesylate (Osimertinib)
• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Nonsmall-cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN